SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a 1.4 billion dollar convertible debt exchange for equity, a move that has sparked intense debate among investors regarding strategic balance sheet cleanup versus shareholder dilution. The community remains deeply polarized, with vocal bears criticizing management's capital allocation and retail investors debating whether this sets the stage for a potential acquisition or further long-term volatility.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is experiencing significant volatility and heavy volume as traders react to a critical FDA advisory committee meeting concerning its cancer therapy candidate. The stock is a major focal point for speculative betting, with intense community debate over potential approval, short interest dynamics, and the high-stakes binary outcome surrounding an impending PDUFA date.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is experiencing high volatility as investors position themselves ahead of the company's upcoming earnings report, with community sentiment split between short-squeeze potential and concerns over long-term profitability and dilution. While some traders are actively highlighting the stock's significant short interest and growing physical AI narrative, others remain wary of recent downward price pressure and the company's capital-intensive growth phase.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz as investors eagerly await Phase 3 data from the IZAR-1 trial for psoriatic arthritis, with many viewing the company's recent capital raise and institutional backing as evidence of long-term confidence in its nanobody pipeline. Community discourse is heavily focused on the high-stakes 'about a month' timeline set by management, fueling a mix of intense anticipation for best-in-class efficacy results and debates over the timing of potential catalysts versus earnings.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging as investor confidence grows around the rapid commercial success of Briumvi and the strategic expansion of its pipeline into treatment-resistant schizophrenia and myasthenia gravis. The community is actively discussing the stock's potential as a major buyout target for Big Pharma, with many dismissing conservative analyst price targets as disconnected from the company's strong growth trajectory and successful commercial execution.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is attracting heavy attention as the community focuses on its robust fee-based burn mechanics and growing status as a dominant decentralized derivatives exchange. Traders are actively debating its decoupling from broader crypto volatility, driven by institutional interest and significant volume from high-profile assets like pre-IPO contracts.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors react to a significant long-term supply agreement with Coherent for indium phosphide wafer substrates, a move that is being viewed as a critical validation of the company's role in the AI data center supply chain. Community discussion is polarized, with bulls pointing to the contract's capacity reservations as proof of a fundamental supply bottleneck in optical networking, while bears express skepticism about valuation and the impact of ongoing export permit restrictions.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibb is capturing significant market attention following a high-profile report that AstraZeneca is exploring a massive $400 billion merger with the company. Investors are actively debating the potential for industry-wide pharmaceutical consolidation, while others remain focused on the strategic implications for BMY's oncology pipeline and the likelihood of significant cost-cutting synergies.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca's stock is experiencing heightened market attention following reports of potential merger talks with Bristol Myers Squibb, an acquisition that would create a pharmaceutical giant valued at approximately $400 billion. The community is actively debating the strategic merits and antitrust risks of such a massive tie-up, while some investors view the deal as a necessary response to upcoming patent cliffs and a desire for consolidated pharmaceutical dominance.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors react to the company's recent AI-driven digital innovation announcements and active share buyback program. The community remains focused on potential relisting catalysts, store expansion metrics, and the company's competitive standing against legacy coffee chains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HOWL The writing is on the wall (see image below).  What company do you know that is in &#39;strategic alternatives&#39; but still burns 1.1m a quarter on their Pre-clinical unnamed candidates (i.e. the INDUCER pipeline) ?   
THE ANSWER IS:  a company that is planning on selling those pre-clinical assets in the near future.   
 
The theory is as follows:   
--&gt; asset sales first on pre-clinical INDUCER programs to improve cash position  
--&gt; continue WTX-124 and WTX-330 trials until final data release (as stated in PR today) 
 --&gt; if data is good, asset sales of WTX-124, 330, and potentially other INDUKINE assets  
--&gt; final step.. RM the remaining cash and shell, possibly return excess cash to shareholders as a dividend

Giuseppe

StockTwits Web

Werewolf Therapeutics Inc

 The writing is on the wall (see image below).  What company do you know that is in 'strategic alternatives' but still burns 1.1m a quarter on their Pre-clinical unnamed candidates (i.e. the INDUCER pipeline) ?   
THE ANSWER IS:  a company that is planning on selling those pre-clinical assets in the near future.   
 
The theory is as follows:   
--> asset sales first on pre-clinical INDUCER programs to improve cash position  
--> continue WTX-124 and WTX-330 trials until final data release (as stated in PR today) 
 --> if data is good, asset sales of WTX-124, 330, and potentially other INDUKINE assets  
--> final step.. RM the remaining cash and shell, possibly return excess cash to shareholders as a dividend